Ambys Medicines fetches $47m Series A extension
Ambys Medicines, a liver cell therapy platform, has secured a $47 million extension to its Series A financing, raising the total tally to $107 million.
Ambys Medicines, a liver cell therapy platform, has secured a $47 million extension to its Series A financing, raising the total tally to $107 million.
Copyright PEI Media
Not for publication, email or dissemination